WallStreetZenWallStreetZen

NASDAQ: RAPT
Rapt Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for RAPT

Based on 5 analysts offering 12 month price targets for Rapt Therapeutics Inc.
Min Forecast
$10.00-1.77%
Avg Forecast
$23.60+131.83%
Max Forecast
$41.00+302.75%

Should I buy or sell RAPT stock?

Based on 5 analysts offering ratings for Rapt Therapeutics Inc.
Buy
Strong Buy
1 analysts 20%
Buy
2 analysts 40%
Hold
2 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RAPT stock forecasts and price targets.

RAPT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-21
lockedlocked$00.00+00.00%2024-02-21
lockedlocked$00.00+00.00%2024-02-21
lockedlocked$00.00+00.00%2024-02-15
lockedlocked$00.00+00.00%2023-11-15

1 of 1

Forecast return on equity

Is RAPT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
24.42%

Forecast return on assets

Is RAPT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RAPT revenue forecast

What is RAPT's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$49.3M
Avg 2 year Forecast
$202.5M
Avg 3 year Forecast
$404.3M

RAPT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RAPT$10.18$23.60+131.83%Buy
AVIR$4.21N/AN/A
INZY$5.64$19.00+236.88%Buy
CELC$14.35$25.00+74.22%Buy
PRAX$40.48$94.67+133.86%Buy

Rapt Therapeutics Stock Forecast FAQ

Is Rapt Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: RAPT) stock is to Buy RAPT stock.

Out of 5 analysts, 1 (20%) are recommending RAPT as a Strong Buy, 2 (40%) are recommending RAPT as a Buy, 2 (40%) are recommending RAPT as a Hold, 0 (0%) are recommending RAPT as a Sell, and 0 (0%) are recommending RAPT as a Strong Sell.

If you're new to stock investing, here's how to buy Rapt Therapeutics stock.

What is RAPT's revenue growth forecast for 2026-2028?

(NASDAQ: RAPT) Rapt Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Rapt Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RAPT's revenue for 2026 to be $1,695,733,252, with the lowest RAPT revenue forecast at $1,695,733,252, and the highest RAPT revenue forecast at $1,695,733,252. On average, 1 Wall Street analysts forecast RAPT's revenue for 2027 to be $6,965,232,930, with the lowest RAPT revenue forecast at $6,965,232,930, and the highest RAPT revenue forecast at $6,965,232,930.

In 2028, RAPT is forecast to generate $13,906,388,512 in revenue, with the lowest revenue forecast at $13,906,388,512 and the highest revenue forecast at $13,906,388,512.

What is RAPT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RAPT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RAPT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year RAPT price target, the average RAPT price target is $23.60, with the highest RAPT stock price forecast at $41.00 and the lowest RAPT stock price forecast at $10.00.

On average, Wall Street analysts predict that Rapt Therapeutics's share price could reach $23.60 by Feb 21, 2025. The average Rapt Therapeutics stock price prediction forecasts a potential upside of 131.83% from the current RAPT share price of $10.18.

What is RAPT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RAPT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.